Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase
1b clinical trial of SGN-CD33A in combination with standard of care
chemotherapy, including cytarabine and daunorubicin, for patients with
newly diagnosed acute myeloid leukemia (AML). The trial will also
evaluate SGN-CD33A in the consolidation setting for AML, both in
combination with cytarabine and as a single-agent maintenance regimen.
for Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia investment picks